ESTRO 2025 - Abstract Book

S866

Clinical - Gynaecology

ESTRO 2025

Results: Sixteen questionnaires from Italian radiotherapy centres were returned and collected: three centres in the north, six in the centre and seven in the south of Italy. The major of centres are national community hospitals (N = 10, 62.5%), 5 are academic institutions (31.2%), and 1 is other settings (private clinics, etc) (6.2%). Thirteen out of 16 centres reported that they discuss cases in multidisciplinary teams, 11 of them on a weekly basis and 2 on a bi-weekly basis, all of them with 3 or more attending specialists. About guidelines adopted to prescribe adjuvant therapy, whether integrating common risk criteria and molecular risk factors, all centres referred to ESGO-ESTRO-ESP, 3 of them centres referred to adopted also to ESMO and AIOM guidelines. About molecular data, in this survey emerged that p53 and ER/PR are available in all centres and have been obtained through immunohistochemical analysis; also MMR has been obtained through immunohistochemical analysis in 57% of the cases; POLE and MSI have been obtained through molecular analysis in more than 50% of the cases; L1CAM and LCN are available in only 2 centres (L1CAM) and 1 centre (LCN). Four of 16 centres performed the analysis only with one of the two methods, and 1 of them used to send its samples to another centre in the same region. Conclusion: Our survey in collaboration with the Gynecology Study Group of Italian Association of of Radiation and Clinical Oncology gave a panorama of the real Italian treatments for EC and its adherence to guidelines with attention for available molecular factors.

Keywords: Endometrial cancer, molecular data

3964

Digital Poster Cost-effectiveness of locoregional hypofractionated RT in early breast cancer: evaluation alongside the HypoG-01 phase 3 Unicancer trial Aldéric M Fraslin 1,2 , Alexandre Lolivier 1,2 , Robabeh Ghodssi-Ghassemabadi 1,2 , Youlia Kirova 3 , Séverine Racadot 4 , Mohamed Benchalal 5 , Jean Baptiste Clavier 6 , Claire Charra Brunaud 7 , Marie-Eve Fouche-Chand 8 , Delphine Argo Leignel 9 , Karine Peignaux 10 , Ahmed Benyoucef 11 , David Pasquier 12 , Philippe Guilbert 13 , Assia Lamrani-Ghaouti 14 , Marie Bergeaud 14 , Guillaume Auzac 15 , Stefan Michiels 1,2 , Sofia Rivera 15 , Julia Bonastre 1,2 1 Office of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France. 2 Oncostat U1018, INSERM, Villejuif, France. 3 Radiotherapy, Curie, Paris, France. 4 Radiotherapy, Léon Bérard, Lyon, France. 5 Radiotherapy, Eugène Marquis, Rennes, France. 6 Radiotherapy, Paul Strauss, Strasbourg, France. 7 Radiotherapy, Institut de Cancérologie de Lorraine, Nancy, France. 8 Radiotherapy, Antoine Lacassagne, Nice, France. 9 Radiotherapy, Hôpital du Scorff, Lorient, France. 10 Radiotherapy, Georges François Leclerc, Dijon, France. 11 Radiotherapy, Henri Becquerel, Rouen, France. 12 Radiotherapy, Centre Oscar Lambret, Lille, France. 13 Radiotherapy, Jean Godinot, Reims, France. 14 UNITRAD, UNICANCER, Kremlin Bicêtre, France. 15 Department of Radiation Oncology, Gustave Roussy, Villejuif, France